Atezolizumab
Phase 3Terminated 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Carcinoma, Transitional Cell
Conditions
Carcinoma, Transitional Cell
Trial Timeline
Oct 5, 2015 → Jun 14, 2022
NCT ID
NCT02450331About Atezolizumab
Atezolizumab is a phase 3 stage product being developed by Roche for Carcinoma, Transitional Cell. The current trial status is terminated. This product is registered under clinical trial identifier NCT02450331. Target conditions include Carcinoma, Transitional Cell.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07284121 | Pre-clinical | Recruiting |
| NCT05770102 | Phase 2/3 | Recruiting |
| NCT05300282 | Phase 1/2 | Recruiting |
| NCT05047250 | Phase 3 | Active |
| NCT05038657 | Phase 2 | UNKNOWN |
| NCT05171777 | Phase 2 | Completed |
| NCT05470595 | Phase 2 | Active |
| NCT04624399 | Phase 2 | Recruiting |
| NCT04660344 | Phase 3 | Active |
| NCT04321330 | Phase 2 | Completed |
| NCT04462276 | Phase 2 | Completed |
| NCT04273061 | Phase 2 | Recruiting |
| NCT03548428 | Phase 2 | Recruiting |
| NCT04221529 | Phase 2 | Completed |
| NCT03922997 | Phase 3 | Completed |
| NCT03976518 | Phase 2 | Completed |
| NCT03782207 | Pre-clinical | Active |
| NCT03697850 | Phase 2 | Active |
| NCT03357224 | Phase 2 | Terminated |
| NCT03559647 | Pre-clinical | Completed |
Competing Products
20 competing products in Carcinoma, Transitional Cell